Our Story

Michael joined Brandon Capital in 2016.

He and has since played a key role in evaluating and executing new investments. He currently serves as a director of Cincera Therapeutics Pty Ltd, Foray Therapeutics Pty Ltd, and Currus Biologics Pty Ltd, and led due diligence on the firm’s recent investment in AdvanCell Isotopes Pty Ltd. Additionally, he is the Acting Project Head at CUREator, Australia’s national biotech incubator, which provides significant non-dilutive funding and expert guidance to early-stage biotech ventures.

Before joining Brandon Capital, Michael was a Senior Business Development Manager at Monash University, where he managed the Life Sciences portfolio for the Faculty of Medicine. He led the filing of multiple patent families on new research opportunities, resulting in licensing deals with global pharmaceutical companies such as Hoffman La Roche and emerging biotechnology companies such as ArsenalBio.

Earlier in his career, Michael was an Investment Manager (Life Sciences) at TTCF, a seed/venture commercialisation fund focused on academic research-driven opportunities. At TTCF, he led due diligence and deal negotiations for multiple life sciences transactions, including Nexvet Biopharma (NASDAQ: NVET), which was acquired by Zoetis in 2017. Nexvet’s monoclonal antibody assets, now marketed as Solensia and Librela, have been projected by Zoetis to generate peak revenues exceeding US$1 billion.

Michael’s research background includes a Roche Research Foundation postdoctoral fellowship at ISREC (EPFL) in Lausanne, Switzerland. He holds a Bachelor of Science (First-Class Honours) and a PhD in stem cell biology from the University of Adelaide, as well as an MBA in technology management from La Trobe University. He is also a graduate of the Australian Institute of Company Directors (AICD).